Most of the contraindications to the administration of intravenous (IV) recombinant tissue plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These were derived from expert consensus for the National Institute of Neurological Disorders and Stroke (NINDS) trial. Despite the fact that the safety and efficacy of IV rtPA has been repeatedly confirmed in large international observational studies over the past 20 years, most patients with acute ischemic stroke disappointingly still do not receive thrombolytic treatment. Some of the original exclusion criteria have proven to be unnecessarily restrictive in real-world clinical practice. It has been suggested that application of relaxed exclusion criteria might increase the IV thrombolysis rate up to 20% with comparable outcomes to thrombolysis with more conventional criteria. We review the absolute and relative contraindications to IV rtPA for acute ischemic stroke, discussing the underlying rationale and evidence supporting these exclusion criteria.
JauchECSaverJLAdamsHPJr. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.
2.
MeretojaAPutaalaJTatlisumakT. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41(7):1450–1458.
3.
KvistadCELogalloNThomassenL. Safety of off-label stroke treatment with tissue plasminogen activator. Acta Neurol Scand. 2013;128(1):48–53.
4.
KatoHIzumiyamaMIzumiyamaKTakahashiAItoyamaY. Silent cerebral microbleeds on T2*-weighted MRI: correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke. 2002;33(6):1536–1540.
5.
FiehlerJAlbersGWBoulangerJM. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007;38(10):2738–2744.
6.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–1587.
7.
AhmedNWahlgrenNBraininM. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40(7):2442–2449.
8.
DemchukAMTanneDHillMD. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57(3):474–480.
9.
LarrueVvon KummerRRMullerABluhmkiE. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–441.
10.
BrottTLuMKothariR. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998;29(8):1504–1509.
11.
AlbersGWBatesVEClarkWMBellRVerroPHamiltonSA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145–1150.
12.
TsivgoulisGSaqqurMSharmaVKLaoAYHillMDAlexandrovAV. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke. 2007;38(9):961–966.
13.
TanneDKasnerSEDemchukAM. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105(14):1679–1685.
14.
KatzanILFurlanAJLloydLE. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283(9):1151–1158.
15.
Lopez-YunezAMBrunoAWilliamsLSYilmazEZurruCBillerJ. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. 2001;32(1):12–16.
BreuerLBlinzlerCHuttnerHBKiphuthICSchwabSKohrmannM. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke’. Cerebrovasc Dis. 2011;32(2):177–185.
18.
TopakianRGruberFFellnerFAHaringHPAichnerFT. Thrombolysis beyond the guidelines: two treatments in one subject within 90 hours based on a modified magnetic resonance imaging brain clock concept. Stroke. 2005;36(11):e162–e164.
19.
BrunnerFTomandlBSchroterA. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur J Neurol. 2011;18(12):1407–1411.
20.
FrankBGrottaJCAlexandrovAV. Thrombolysis in stroke despite contraindications or warnings?Stroke. 2013;44(3):727–733.
21.
GiuglianoRPMcCabeCHAntmanEM. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001;141(5):742–750.
22.
MazyaMEgidoJAFordGA. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43(6):1524–1531.
23.
XianYLiangLSmithEE. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA. 2012;307(24):2600–2608.
24.
European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457–507.
25.
MatuteMCMasjuanJEgidoJA. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis. 2012;33(3):231–239.
26.
KimYDLeeJHJungYH. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci. 2010;298(1-2):101–105.
27.
SeetRCZhangYMooreSAWijdicksEFRabinsteinAA. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke. 2011;42(8):2333–2335.
28.
IbrahimMMSebastianJHussainM. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?Cerebrovasc Dis. 2010;30(5):508–513.
29.
PrabhakaranSRivoltaJVieiraJR. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010;67(5):559–563.
30.
RueckerMMatosevicBWilleitP. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology. 2012;79(1):31–38.
31.
VergouwenMDCasaubonLKSwartzRH. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke. 2011;42(4):1041–1045.
32.
MiedemaILuijckxGJDe KeyserJKochMUyttenboogaartM. Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2012;83(5):537–540.
33.
CoyleDCoyleKCameronC. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498–506.
34.
MatuteMCGuillanMGarcia-CaldenteyJ. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost. 2011;106(1):178–179.
35.
De SmedtADe RaedtSNieboerKDe KeyserJBrounsR. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010;30(5):533–534.
36.
LeeVHConnersJJPrabhakaranS. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis. 2012;21(8):916. e911–e912.
37.
MarroneLCMarroneAC. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis. 2012;34(3):246–247.
38.
SanghaNEl KhouryRMisraVLopezG. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis. 2012;21(8):917 e915–918.
39.
BarretoADAlexandrovAVLydenP. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012;43(3):770–775.
40.
BlommelMLBlommelAL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011;68(16):1506–1519.
41.
GrangerCBAlexanderJHMcMurrayJJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
42.
PatelMRMahaffeyKWGargJ. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
43.
YongAWMorrisZShulerKSmithCWardlawJ. Acute symptomatic hypoglycaemia mimicking ischaemic stroke on imaging: a systemic review. BMC Neurol. 2012;12:139.
44.
RiboMMolinaCMontanerJ. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke. 2005;36(8):1705–1709.
45.
RiboMMolinaCADelgadoP. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA. J Cerebral Blood Flow Metab. 2007;27(9):1616–1622.
46.
BrunoALevineSRFrankelMR. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59(5):669–674.
47.
DemchukAMMorgensternLBKriegerDW. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30(1):34–39.
48.
SaurDKucinskiTGrzyskaU. Sensitivity and interrater agreement of CT and diffusion-weighted MR imaging in hyperacute stroke. AJNR Am J Neuroradiol. 2003;24(5):878–885.
49.
von KummerRAllenKLHolleR. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1997;205(2):327–333.
HackeWKasteMBluhmkiE. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
52.
HackeWKasteMFieschiC. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–1025.
53.
HackeWKasteMFieschiC. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–1251.
54.
BamfordJSandercockPDennisMBurnJWarlowC. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project—1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 1990;53(1):16–22.
55.
KammersgaardLPJorgensenHSReithJNakayamaHPedersenPMOlsenTS. Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study. Age Ageing. 2004;33(2):149–154.
56.
SandercockPWardlawJMLindleyRI. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–2363.
57.
MishraNKAhmedNAndersenG. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ. 2010;341:c6046.
58.
BerrouschotJRotherJGlahnJKucinskiTFiehlerJThomallaG. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke. 2005;36(11):2421–2425.
59.
EngelterSTReichhartMSekoranjaL. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology. 2005;65(11):1795–1798.
60.
CostelloCACampbellBCPerez de la OssaN. Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis. J Clin Neurosci. 2012;19(3):360–363.
61.
SylajaPNCoteRBuchanAMHillMD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006;77(7):826–829.
62.
RinglebPASchwarkCKohrmannM. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry. 2007;78(7):690–693.
63.
MouradianMSSenthilselvanAJicklingG. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005;76(9):1234–1237.
64.
van OostenbruggeRJHuppertsRMLodderJ. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry. 2006;77(3):375–377.
65.
SmithEEFonarowGCReevesMJ. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines-stroke. Stroke. 2011;42(11):3110–3115.
66.
RajajeeVKidwellCStarkmanS. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology. 2006;67(6):980–984.
67.
NedeltchevKSchweglerBHaefeliT. Outcome of stroke with mild or rapidly improving symptoms. Stroke. 2007;38(9):2531–2535.
68.
KimJTParkMSChangJLeeJSChoiKHChoKH. Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS One. 2013;8(8):e70996.
69.
SmithEEAbdullahARPetkovskaIRosenthalEKoroshetzWJSchwammLH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke. 2005;36(11):2497–2499.
70.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med. 2005;46(3):243–252.
71.
KohrmannMNoweTHuttnerHB. Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis. 2009;27(2):160–166.
72.
Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28(11):2119–2125.
73.
SylajaPNDongWGrottaJC. Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocrit Care. 2007;6(3):181–185.
74.
SchonewilleWJWijmanCAMichelP. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol. 2009;8(8):724–730.
75.
ShintonRAGillJSMelnickSCGuptaAKBeeversDG. The frequency, characteristics and prognosis of epileptic seizures at the onset of stroke. J Neurol Neurosurg Psychiatry. 1988;51(2):273–276.
76.
WinklerDTFluriFFuhrP. Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke. 2009;40(4):1522–1525.
77.
ChernyshevOYMartin-SchildSAlbrightKC. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology. 2010;74(17):1340–1345.
78.
ZinkstokSMEngelterSTGensickeH. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013;44(4):1080–1084.
79.
TsivgoulisGAlexandrovAVChangJ. Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series. Stroke. 2011;42(6):1771–1774.
80.
ForsterAGriebeMWolfMESzaboKHennericiMGKernR. How to identify stroke mimics in patients eligible for intravenous thrombolysis?J Neurol. 2012;259(7):1347–1353.
81.
SelimMKumarSFinkJSchlaugGCaplanLRLinfanteI. Seizure at stroke onset: should it be an absolute contraindication to thrombolysis?Cerebrovasc Dis. 2002;14(1):54–57.
82.
GiraldoEAKhalidAZandR. Safety of Intravenous Thrombolysis within 4.5 h of symptom onset in patients with negative post-treatment stroke imaging for cerebral infarction. Neurocrit Care. 2011;15(1):76–79.
83.
De Los RiosFKleindorferDOGuzikA. Intravenous Fibrinolysis eligibility: a survey of stroke clinicians’ practice patterns and review of the literature. J Stroke Cerebrovasc Dis. 2014;23(8):2130–2138.
84.
De SilvaDAManzanoJJChangHMWongMC. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology. 2011;76(21):1838–1840.
85.
DhandANakagawaKNagpalS. Cardiac rupture after intravenous t-PA administration in acute ischemic stroke. Neurocrit Care. 2010;13(2):261–262.
86.
KasnerSEVillar-CordovaCETongDGrottaJC. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology. 1998;50(6):1857–1859.
87.
KremenSAWuMNOvbiageleB. Hemopericardium following intravenous thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2005;20(6):478–479.
88.
GarciaAMEgidoJAGarciaMESimalP. Thrombolysis for ischaemic stroke and glioblastoma multiforme: a case report. BMJ Case Rep. 2009;2009.
89.
NeilWOvbiageleB. Intravenous thrombolysis in ischemic stroke patients with intracranial neoplasms: two cases and a literature review. Case Rep Med. 2011;2011:503758.
90.
EtgenTSteinichIGsottschneiderL. Thrombolysis for ischemic stroke in patients with brain tumors. J Stroke Cerebrovasc Dis. 2014;23(2):361–366.
91.
GrimmSADeAngelisLM. Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology. 2007;69(9):936.
92.
JaffeRReichmanJMWeissATZahgerD. Thrombolysis in the presence of an intracranial meningioma. Chest. 1997;111(1):258.
93.
RubinshteinRJaffeRFlugelmanMYKarkabiBLewisBS. Thrombolysis in patients with a brain tumour. Heart. 2004;90(12):1476.
94.
HanSChayaCHooGW. Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor. J Intensive Care Med. 2006;21(4):240–245.
95.
MittalMKSeetRCZhangYBrownRDJrRabinsteinAA. Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms. J Stroke Cerebrovasc Dis. 2013;22(5):639–643.
96.
ShethKNShahNMorovatiTHermannLDCroninCA. Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms. Neurocrit Care. 2012;17(6):199–203.
97.
KimJTParkMSYoonWChoKH. Detection and significance of incidental unruptured cerebral aneurysms in patients undergoing intravenous thrombolysis for acute ischemic stroke. J Neuroimaging. 2012;22(2):197–200.
98.
AlshekhleeALiCCChuangSY. Does dementia increase risk of thrombolysis? A case-control study. Neurology. 2011;76(18):1575–1580.
99.
EdwardsNJKamelHJosephsonSA. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature. Stroke. 2012;43(2):412–416.
100.
BalamiJSHadleyGSutherlandBAKarbalaiHBuchanAM. The exact science of stroke thrombolysis and the quiet art of patient selection. Brain. 2013;136(pt 12):3528–3553.
101.
SaposnikGCoteRRochonPA. Care and outcomes in patients with ischemic stroke with and without preexisting dementia. Neurology. 2011;77(18):1664–1673.
102.
BuslKMNogueiraRGYooAJHirschJASchwammLHRostNS. Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients. J Stroke Cerebrovasc Dis. 2013;22(6):718–724.
103.
SaposnikGKapralMKCoteR. Is pre-existing dementia an independent predictor of outcome after stroke? A propensity score-matched analysis. J Neurol. 2012;259(11):2366–2375.
